The Vetr crowd on Monday upgraded its rating on Antares Pharma Inc (NASDAQ:ATRS) from 3 stars (Hold), issued four days ago, to 5 stars (Strong Buy). Crowd sentiment at the time of the upgrade was unanimously positive, with 100 percent of Vetr user ratings bullish.
The Vetr upgrade comes as share price in the biotech company has corrected after spiking to a more than three-year high of 3.89 near the start of the month when it delivered strong revenue in its second-quarter earnings report. Most of the correction occurred after the company reported a negative note from the FDA on deficiencies in its XYOSTED NDA filing. By the close of Monday's session, Antares was trading at $2.10.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average price target for Antares is up at $3.69, which is above the average analyst price target of $3.10. Less than 2 percent of Vetr users are holding $ATRS in their watch-lists.